Additionally, markers associated with liver fibrosis include AST/ALT; the 2018 edition of China’s MAFLD treatment guidelines indicate that elevated concentrations of ALT, AST, and other biomarkers significantly increase the incidence of MAFLD and MASH [57]. Here, GPT is linked to Hepatic fibrosis.